Innovent Biologics
Innovent Biologics is one of the Best Biotech Companies in China. It is best known for its collaboration with Eli Lilly on the PD-1 inhibitor Tyvyt (sintilimab), co-invented by Innovent CEO Michael Yu and approved in China in December 2018 for relapsed or refractory classic Hodgkin's lymphoma (cHL) after at least two prior lines of therapy.
Dozens of PD-1/L1 medicines are being developed in China amid an I-O mania, all expecting to mimic or even outperform Bristol Myers Squibb's Opdivo and Merck's Keytruda clinical results. According to Frost & Sullivan, the Chinese PD-1 market will contribute $13.1 billion to the global PD-1 market of $78.9 billion by 2030. Innovent is definitely one of those touting best-in-class potential for its candidate. Its optimism is based on Tyvyt’s higher affinity to its target compared with Keytruda and Opdivo, and it appears to occupy more of the PD-1 binding sites than Opdivo.
Innovent makes developing and selling “high quality biopharmaceutical products that are affordable to ordinary people” as its mission. Guided by that motto—and a goal of quickly snaring market share amid increasingly heated competition—Innovent and Lilly this year cut Tyvyt’s price by 64% to become the first and only PD-1 covered by China’s National Reimbursement Drug List. In the first half of 2020, Innovent recorded Tyvyt sales of CNY 920.9 million ($137.4 million).
Headquarters: 168 Dongping Street, Suzhou Industrial Park,Jiangsu 215123, China
CEO: De-Chao Michael Yu
Founded: 2011
Website: https://www.innoventbio.com/
